Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
OncoMed Pharmaceuticals Inc (OMED) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/23/2019 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of OncoMed Pharmaceuticals, Inc",
"Amended and Restated Bylaws of OncoMed Pharmaceuticals, Inc"
04/17/2019 8-K Submission of Matters to a Vote of Security Holders, Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 17, 2019 ONCOMED PHARMACEUTICALS, INC. Delaware 001-35993 38-3572512 800 Chesapeake Drive Redwood City, California 94063 Registrant's telephone number, including area code: 995-8200 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen..."
03/15/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Contingent Value Rights Agreement, by and between OncoMed Pharmaceuticals, Inc. and Computershare Inc., as rights agent",
"Form of Stockholder Support Agreement",
"OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights REDWOOD CITY, Calif., March 15, 2019 — OncoMed Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special dividend in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed or its affiliates of certain contingent cash amounts in the future following the exercise by Celgene Corporation or certain of Celgene Corporation's affiliates of the exclusive option granted by OncoMed to Celgene in relation to OncoMed's etigilimab product. More specifically, if a specified approval or sales milestone is achi..."
03/07/2019 8-K Quarterly results
01/28/2019 8-K Quarterly results
12/06/2018 8-K Investor presentation, Acquisition/merger/asset purchase announced
Docs: "SIGNATURES",
"Agreement and Plan of Merger and Reorganization, by and among Mereo BioPharma Group plc, Mereo US Holdings Inc., Mereo MergerCo One Inc. and OncoMed Pharmaceuticals, Inc",
"Form of Stockholder Support Agreement, by and between Mereo BioPharma Group plc and certain stockholders of OncoMed Pharmaceuticals, Inc",
"Form of Shareholder Support Agreement, by and between OncoMed Pharmaceuticals, Inc. and certain officers and directors of Mereo BioPharma Group plc",
"Shareholder Support Agreement, by and between OncoMed Pharmaceuticals, Inc. and Novartis Pharma AG",
"Shareholder Support Agreement, by and between OncoMed Pharmaceuticals, Inc. and Invesco Asset Management Limited, as agent for and on behalf of its discretionary managed client, Invesco High Income Fund",
"Shareholder Support Agreement, by and between OncoMed Pharmaceuticals, Inc. and Invesco Asset Management Limited, as agent for and on behalf of its discretionary managed client, Invesco Income Fund",
"Shareholder Support Agreement, by and between OncoMed Pharmaceuticals, Inc. and Invesco Asset Management Limited, as agent for and on behalf of its discretionary managed client, Invesco UK Strategic Income Fund",
"Form of CVR Agreement",
"Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals",
"Investor Presentation"
11/01/2018 8-K Quarterly results
Docs: "OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights -Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer"
10/17/2018 8-K Quarterly results
10/01/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/20/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "About Navicixizumab OncoMed's anti-DLL4/VEGF bispecific antibody, navicixizumab, is designed to inhibit the function of both DLL4 and VEGF and thereby induce potent anti-tumor responses while mitigating certain angiogenic-related toxicities. Navicixizumab was developed utilizing OncoMed's BiMAb ™ bispecific platform technology, which enables the design of bispecific antibodies comparable to traditional monoclonal antibodies but possessing dual target-binding specificity. In preclinical studies, navicixizumab demonstrated robust in vivo anti-tumor efficacy across a range of solid tumor xenografts, including colon, ovarian, lung and pancreatic cancers, among others. Further, in preclinical studies dual inhibition of DLL4 and VEGF appeared to exhibit synergistic anti-tumor activity at d..."
08/02/2018 8-K Quarterly results
Docs: "OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights -Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018-"
06/25/2018 8-K Submission of Matters to a Vote of Security Holders
05/08/2018 8-K Quarterly results
Docs: "OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights Q1 Cash Balance of $88.4 Million—Cash through Q3 2019 First patient expected to be dosed in Phase 1b portion of anti-TIGIT trial in second quarter of 2018"
03/19/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights Navicixizumab and anti-TIGIT data expected in the 2nd Half of 2018"
01/31/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/04/2018 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "FORM 8-K",
"OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program"
11/02/2017 8-K Quarterly results
Docs: "OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation"
09/19/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
07/10/2017 8-K Form 8-K - Current report:
06/05/2017 8-K Form 8-K - Current report
05/08/2017 8-K Form 8-K - Current report
04/28/2017 8-K Form 8-K - Current report
04/17/2017 8-K Form 8-K - Current report
04/10/2017 8-K Form 8-K - Current report
03/08/2017 8-K Form 8-K - Current report
01/05/2017 8-K Form 8-K - Current report
12/06/2016 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report
08/23/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, among OncoMed Pharmaceuticals, Inc. and Leerink Partners LLC, as representative of the underwriters named therein",
"Opinion of Latham & Watkins LLP"
08/09/2016 8-K Quarterly results
Docs: "OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results"
06/24/2016 8-K Submission of Matters to a Vote of Security Holders
05/05/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy